
    
      The investigators will conduct a single-center, prospective, open-label, randomized study to
      evaluate the difference in neurocognitive side effects between Envarsus and immediate release
      tacrolimus. Eligible patients will be enrolled within 8 weeks post-transplantation. They will
      be administered a baseline panel of neurocognitive tests. They will then be randomized to
      either continue on immediate release tacrolimus or Envarsus. 6 weeks after randomization, the
      neurocognitive tests will be repeated.
    
  